Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02717156
Title Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Southern California

transitional cell carcinoma


Pembrolizumab + sEphB4-HSA

Age Groups: adult
Covered Countries USA

No variant requirements are available.